Ex vivo– and in vivo–induced dead tumor cells as modulators of antitumor responses
- 19 October 2010
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1209 (1) , 109-117
Abstract
Joint application of standard tumor therapies like radiotherapy and/or chemotherapy with immune therapy has long been considered not to fit. However, it has become accepted that immune responses may contribute to the elimination of cancer cells. We present how in vivo–induced tumor cell death by irradiation, chemotherapeutic agents, or hyperthermia can be rendered more immunogenic. High hydrostatic pressure is introduced as an innovative inactivation method for tumor cells used as vaccines. Annexin A5, being a natural occurring ligand for phosphatidylserine that is exposed by dying tumor cells, renders apoptotic tumor cells immunogenic and induces tumor regression. Combinations of irradiation with hyperthermia may also foster antitumor responses. For preparation of autologous tumor cell vaccines, high hydrostatic pressure is suitable to induce immunogenic cancer cell death. Future work will be aimed toward evaluating which combination and chronological sequence of radiotherapy, chemotherapy, hyperthermia, annexin A5, and/or autologous tumor cell vaccines will induce specific and long‐lasting antitumor immunity.Keywords
This publication has 49 references indexed in Scilit:
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- Phosphatidylserine targeting for diagnosis and treatment of human diseasesApoptosis, 2010
- Phospholipids: Key Players in Apoptosis and Immune RegulationMolecules, 2009
- Harnessing Dendritic Cells to Generate Cancer VaccinesAnnals of the New York Academy of Sciences, 2009
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrationsJournal of Translational Medicine, 2009
- Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cellsThe FASEB Journal, 2009
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccinesCancer Immunology, Immunotherapy, 2008
- Immunogenicity of anthracyclines: moving towards more personalized medicineTrends in Molecular Medicine, 2008
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- Pressure–temperature phase diagrams of biomoleculesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2002